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The bifunctional Neurospora crassa mitochondrial tyrosyl-tRNA synthetase 
(N. crassa mt TyrRS; CYT-18 protein) promotes the splicing of multiple group I 
introns by stabilizing the catalytically active intron structures. CYT-18, and mt 
TyrRS’s from related fungal species, have evolved to promote group I intron splicing 
partly by accumulation of three N-terminal domain insertions that create a structure-
stabilizing scaffold for critical tertiary interactions between the two major group I 
intron domains. The primarily α-helical N-terminal insertion, H0, contributes to 
protein stability and is necessary for splicing the N. crassa ND1 intron, but is 
dispensable for splicing the N. crassa mt LSU intron. Herein, I show CYT-18 with a 
complete H0 deletion retains residual ND1 intron splicing activity and addition of the 
missing N-terminus in trans restores a significant portion of its splicing activity. This 
peptide complementation assay revealed important characteristics of the CYT-
18/group I intron interaction including the stoichiometry of H0 in intron splicing and 
  
the importance of specific H0 residues. Evaluation of truncated H0 peptides in this 
assay also suggests a previously unknown structural role of the first five N-terminal 
residues of CYT-18. These residues interact directly with another splicing insertion, 
making H0 a central structural element responsible for connecting all three N-
terminal splicing insertions. 
Transitioning to a separate study, I have demonstrated that enzymes retain 
catalytic activity when captured in the solvent channels of three-dimensional (3D) 
DNA crystals. Using RNase A as a model enzyme system this work shows that 
crystals infused with enzyme can cleave a fluorescent dinucleotide substrate with 
similar kinetic restrictions as other immobilized enzyme systems, mainly limited by 
diffusion of substrate. This new vehicle for immobilized enzymes, created entirely 
from biomolecules, provides a platform for developing modular solid-state catalysts 
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PART I: A NEW ROLE FOR THE CYT-18 N-TERMINUS 
 
Chapter 1: Introduction 
1.1 Group I introns  
Introns are the non-coding regions of a gene that must be properly removed by 
RNA splicing from exons.1, 2 According to the specific splicing mechanisms, several 
classes of introns have been identified, including spliceosomal introns, tRNA introns, 
as well as group I and group II introns.1 Through the past thirty years of intense study, 
group I introns have become the best understood, with respect to their tertiary RNA 
structure and splicing mechanism.3-8  
Group I introns are widely distributed in bacteria, viruses, chloroplasts, and 
mitochondrial genomes but are not found in humans.9, 10 Being the first RNAs that are 
demonstrated to be catalytically active11, 12, group I introns utilize a splicing 
mechanism10 that begins with the attack of the 3’ hydroxyl group of a guanosine at 
the 5’ splice site and is followed by the attack of the 3’ hydroxyl of the 5’ exon at the 
3’ exon. The splicing is completed with the ligation of two exons and the excision of 
the intron (Figure 1.1). Group I introns have limited sequence homology but share 
conserved secondary/tertiary structures5-7 and the same splicing mechanism10. The 
conserved group I intron secondary structure consists of base-paired regions (P), 
junction regions (J) between the base-paired helices, and loop regions (L) that join the 
base-paired stem regions (Figure 1.2A).5 Nine conserved base-paired regions (P1-P9) 




juxtaposed to form the active site cleft for splicing when they are aligned in the right 
orientation (Figure 1.2B).3-5, 13, 14 The J3/4 and J6/7 nucleotide triples in P6’s minor 
groove and P4’s major groove are important in determining the relative orientation of 
the P4-P6 and P3-P9 domains.3-5, 15 In addition, the tetraloop-tetraloop receptor 
interactions between L9 and P5,13 interactions between L2 and P8,16 and interactions 
between P5abc and other peripheral elements and the catalytic core17 all provide 
further stability. Though some group I introns can self-splice in vitro, requiring only 
guanosine and magnesium, many group I introns including N. crassa ND1 and 
mitochondrial LSU introns are not capable of efficient splicing without the aid of 
cofactors in vivo.15 Many protein splicing cofactors have been studied.18-23 The first 
discovered and most extensively studied is CYT-18, a protein splicing cofactor 
promoting the splicing of group I introns primarily by binding and stabilizing a 










Figure 1.1 - Splicing mechanism for group I intron.  
Group I introns utilizes a splicing mechanism through two trans-esterification 
reactions. It begins with the attack of the 3’ hydroxyl group of a guanosine at the 5’ 
splice site and is followed by the attack of the 3’ hydroxyl of the 5’ exon at the 3’ 













Figure 1.2 - Secondary structure (A) and tertiary structure (B) of group I intron 
Tetrahymena ribozyme.  
(A) Conserved helical base-pairing regions are designated P1 through P9.2, and 
joining regions are designated with a “J”. P4-P6 domain is colored in green, P3-P9 
domain is colored in red, and the peripheral extensions are colored in black. (B) 
Tertiary crystal structure of the Tetrahymena thermophila rRNA LSU group I intron, 
showing P4-P6 and P3-P9 domains juxtaposed to form the active site for splicing. 





1.2 CYT-18 and the N-terminal extension H0 
The N. crassa mitochondrial tyrosyl-tRNA synthetase (mt TyrRS; CYT-18 
protein) and the mt TyrRS’s from other Pezizomycotina fungi are multifunctional 
proteins responsible for aminoacylating mt tRNATyr and promoting mt group I intron 
splicing.24, 30 CYT-18 is a homodimer, which binds one molecule of group I intron 
RNA.31 Previous studies showed that CYT-18 recognizes conserved structural 
features of the group I intron catalytic core and promotes splicing by stabilizing the 
catalytically active RNA structure.25-27 Chemical structure modification analysis 
showed that CYT-18 does not recognize introns in a sequence-specific manner but 
instead recognizes the three-dimensional structure of the phosphodiester backbone.27, 
28 Though group I intron primary sequences can vary greatly, their conserved three-
dimensional structures allow CYT-18 to recognize and promote splicing of diverse 
group I introns.26, 32-34 Biochemical and genetic experiments led to a model describing 
how CYT-18 functions in splicing; first interacting with the intron P4−P6 domain and 
then contacting the P3−P9 domain, which stabilizes the two extended RNA domains 
in the correct orientation relative to non-native structures to generate a catalytically 
active intron conformation.25-27, 32, 35 
Similar to CYT-18, the bacterial TyrRS’s are homodimers, which bind and 
aminoacylate one molecule of tRNATyr (“half-of-sites reactivity”).36 The extensively 
studied structures of bacterial TyrRS’s are comprised of an N-terminal nucleotide-
binding fold, an intermediate α-helical domain, and a C-terminal tRNA-binding 
domain, which fold into a structurally conserved TyrRS core.37 Sequence analysis 




positionally conserved distinct insertions, including an N-terminal extension (H0), 
two small insertions in the catalytic domain (Ins1 and Ins2), and three insertions in 
the C-terminal domain (Ins3, Ins4, and Ins5), which are absent in the bacterial 
TyrRS’s or yeast mt TyrRS.30, 38 Superimposition of the crystal structures of a C-
terminally truncated CYT-18 and Bacillus stearothermophilus TyrRS demonstrate 
close structural similarity in their TyrRS cores including the nucleotide-binding fold 
and α-helical intermediate domain except for the three CYT-18-specific insertions 
(Figure 1.3).39 Despite the significant structural homology between bacterial and mt 
TyrRS’s, the activity to promote group I intron splicing has only been demonstrated 
for mt TyrRS’s of fungi (Aspergillus nidulans, Histoplasma capsulatum and 











Figure 1.3 - Ribbon diagram showing structural overlap of the nucleotide 
binding fold and α-helical domains of monomeric CYT-18/ΔC424−669 and B. 
stearothermophilus TyrRS.  
The B. stearothermophilus TyrRS monomer structure (purple, PDB ID: 3TS137) was 
superimposed on that of CYT-18 (cyan and green, PDB ID: 1Y4239). CYT-18-





Of the three N-terminal insertions, the N-terminal extension H0 has the 
highest sequence conservation among the Pezizomycotina mt TyrRS’s and is the most 
thoroughly studied biochemically.30, 40 H0 (residues 33-61) is primarily an 
amphipathic α-helix (residues 39-60) that represents the first regular secondary 
structural element of CYT-18 following cleavage of the mt targeting peptide (residues 
1-32). Previous biochemical studies demonstrated that H0 is important for intron 
splicing but dispensable for the tyrosyl tRNA synthetase activities.40 In the previous 
work, all the CYT-18 N-terminal truncations tested partially retained the N-terminal-
most residues and began only after Phe37. Deletion of as few as four residues 
(Δ38−41) abolished the splicing activity.38 However, an even more extensive deletion 
that included the entire H0 α-helix (Δ38−59) retained the splicing activity for the mt 
LSU intron but was unable to splice the N. crassa ND1 intron.40 Conversely, the C-
terminal domain of CYT-18 was required for splicing the N. crassa mt LSU intron 
but was dispensable for splicing the ND1 intron. This observed differential 
dependence on these structural elements suggested that CYT-18 utilizes different 
regions to compensate for different RNA structural defects in non-self-splicing group 
I introns.40 
Structures mainly resulting from X-ray crystallography have provided 
significant information for elucidating the structural and functional role of H0 in 
group I intron splicing. The crystal structure of a C-terminally truncated CYT-18 
(CYT-18/Δ424−669) showed that H0 is connected to the highly conserved TyrRS 
core through Gly62 and H0 is stabilized against the protein core by primarily 




This structural evidence is consistent with the genetic experiments that identified 
these residues as among the most highly conserved in splicing-competent proteins 
from H0 mutant libraries.40 However, due to the weak electron density and ambiguity 
of the seven N-terminal-most residues of H0 (including the initiating Met that is not 
present in the mature protein in mt) and the flexible C-terminal residues from a 
symmetry-related monomer, these N-terminal residues were not built in the crystal 
structure.39 
Another structure of a splicing-active C-terminally truncated CYT-18 protein 
(CYT-18/Δ424−669) co-crystallized with a group I intron RNA (the bacteriophage 
Twort orf142-I2 ribozyme) revealed key structural features of RNA-protein 
interactions (Figure 1.4). It showed that H0, Ins1, and Ins2 from one subunit (Subunit 
B) of the homodimer, directly interact with the group I intron catalytic core and 
stabilize and/or promote key tertiary RNA-protein interactions.15 The structural 
information revealed by this work indicate that H0 and Ins1 of one subunit interact 
with each other through side chain contacts to form a distinct structural scaffold for 
group I intron binding at its junction of the two RNA domains, with Ins2 of the same 
CYT-18 subunit interacting in the minor groove of the intron’s P9 helix. Based on the 
co-crystal structure, H0 from one subunit of the CYT-18 dimer assists in establishing 
the correct orientation of the P4-P6 and P3-P9 of the group I intron through 
interactions with the two major junctions, J3/4 and J6/7, as well as P7. H0 from the 
other subunit of the CYT-18 dimer is in close proximity to the P5 domain of the 
group I intron, but its role in group I intron splicing is not clear. Although the co-










Figure 1.4 - Cartoon diagram showing CYT-18 interacting and stabilizing the 
Twort orf142-I2 intron structure.  
CYT-18 (right, two subunits are colored grey and black) interacts with the intron’s 
P4−P6 domain (middle, green), followed by contacts with the P3−P9 domain (left, 
red) that stabilize the two extended RNA domains in the correct orientation relative to 
non-native structures to generate a catalytically active intron conformation. The group 
intron domains are colored as in Figure 1.2. J3/4 and J6/7 are colored in blue; ωG is 






This prior work allowed me to expand on the structural and functional roles of 
H0 in group I intron splicing and pioneer an in vitro peptide complementation 
splicing assay. Studies on the first complete H0 deletion on CYT-18 (CYT-
18/Δ33−61) showed that it retains residual splicing activity. My work herein shows 
the splicing activity of CYT-18/Δ33−61 is significantly restored by the addition of the 
N-terminal H0 peptide in trans. Titration experiments coupled with burst kinetic 
analysis indicate that H0 bound to one subunit of the CYT-18 dimer is sufficient to 
promote splicing of the group I intron. The failure of short N-terminally truncated H0 
peptides to restore splicing in this assay and the inability of a CYT-18 mutant lacking 
just the first five H0 residues to promote splicing indicate a previously unrecognized 
role for the N-terminal-most residues of CYT-18. A reanalysis of the CYT-
18/Δ424−669 crystal structure indicates that these N-terminal residues interact 
directly with Ins2, which provides a new role for H0 as a structural link connecting all 






Chapter 2: Experimental Procedures  
2.1 Protein expression and purification 
The wild-type CYT-18 protein was expressed in Escherichia coli (E. coli) 
HMS174(DE3) cell from plasmid pEX56040 and purified by polyethyleneimine (PEI) 
precipitation31 and ion-exchange chromatography with 15-Q and 15-S columns (GE 
Healthcare Bio-Sciences, Pittsburgh, PA), with the 15-S column eluted by a linear 
gradient of 0.025-1 M KCl in 25 mM Tris-HCl (pH 7.5), 10% glycerol. All steps 
were performed at 4 °C. The CYT-18/Δ33−61 and CYT-18/Δ33−37 open reading 
frames, both with an N-terminal hexahistidine tag followed by a tobacco etch virus 
(TEV) protease recognition sequence, were cloned into expression vector pET-11d 
(Novagen) and confirmed by sequencing. Both proteins were expressed by 
autoinduction41 in E. coli HMS174(DE3) cell and purified by a Ni2+ column, TEV 
cleavage, a second Ni2+ column, and a final Superdex S-200 gel filtration column30. 
All proteins were dialyzed against 25 mM Tris-HCl (pH 7.5), 500 mM KCl, and 50% 
(v/v) glycerol, flash frozen, and stored at − 80 °C. The active concentrations of 
protein were determined by tyrosyl-adenylation assays as described below. 
2.2 Denaturation and renaturation 
Protein denaturation was done by mixing 200 µL of 100 µM CYT-18 dimer 
with1.8 mL of denaturation buffer containing 25 mM Tris-HCl (pH 7.5), 500 mM 
KCl, 2 mM DTT, and 8 M urea, followed by a 10-minute (min) incubation. Protein 
renaturation was done by buffer exchange using an Amicon Ultra 10K MWCO 




centrifugation. A total of 4.5 mL of renaturation buffer containing 25 mM Tris-HCl 
(pH 7.5) and 500 mM KCl was added to the concentrator following concentration to 
250 µL (in the renaturation with H0-WT experiment, 6-fold molar excess of H0-WT 
with respect to the initial concentration of protein is also added). The final protein 
concentrations were determined by UV absorbance at 280 nm (A280) and adjusted to 
500 nM for tyrosyl-adenylation assays (ε280 for CYT-18, CYT-18/Δ33−61 and CYT-
18/Δ33−37 are respectively 96680 M−1 cm−1, 89710 M−1 cm−1, and 96680 M−1 cm−1). 
All steps were performed at 25 °C.  
2.3 Peptide synthesis, expression, and purification 
Except where noted, peptides utilized in the complementation assays were 
chemically synthesized, HPLC-purified, and lyophilized (United Biosystems, 
Herndon, VA and NEO Biolab, Cambridge, MA). These peptides were directly 
dissolved in 10 mM Tris-HCl (pH 7.5), 10 mM KCl, and 50% (v/v) glycerol and 
stored at − 80 °C. Several assays were performed with recombinant H0-WT peptide. 
The H0-WT peptide was cloned into vector pMAL-C2T, expressed via autoinduction 
in E. coli HMS174(DE3) cell as a maltose-binding protein (MBP) fusion that was 
cleavable by TEV protease. The fusion protein was purified by amylose affinity 
chromatography and cleaved by TEV protease overnight at 4°C. The H0-WT peptide 
was further purified by size-exclusion chromatography (Figure 2.1). Both synthetic 
and recombinant peptides were verified by mass spectrometry. Concentrations were 
determined by A280 (ε280 for H0-WT, H0-37, H0-42, and H0-46 are respectively 6970 


















Figure 2.1 - Silver-stained SDS-PAGE gel for H0-WT purification. 
This gel shows the MBP fusion sample after TEV protease treatment and fractions of 
the size exclusion chromatography. The H0-WT peptide, with an estimated molecular 
weight of 3.6 kDa, is quantified to be > 95% pure according to the fraction from 





2.4 Tyrosyl-adenylation assay 
Tyrosyl-adenylation assays were done in 25 µL of reaction containing 500 nM 
protein, 5 mM ATP, 100 mM KCl, 10 mM MgCl2, 144 mM Tris-HCl (pH 7.5), 0.1 
unit of pyrophosphatase, and 5 µCi of L-[3,5-3H]-tyrosine (42.6 Ci mmol−1; Perkin-
Elmer). The reaction was initiated by addition of protein and incubated for 10 min at 
30 °C. The samples were then filtered through nitrocellulose membrane (0.2 µm pore 
size) to retain protein-bound tyrosyl-adenylate. Membranes were counted with a 
Beckman Coulter model LS6500 scintillation counter with ScintiVerse I scintillation 
cocktail (Fisher Scientific). 
2.5 Group I intron splicing 
32P-labeled RNA substrates were synthesized by in vitro transcription from 
linearized plasmids, using MEGAscript kit (Ambion) with 3.3 mM [α-32P] UTP 
(0.445 Ci mmol−1; PerkinElmer).30 Splicing assays were done by adding CYT-18 
protein to 32P-labeled RNA substrate to a final reaction volume of 25 µL containing 5 
mM MgCl2, 25 mM Tris-HCl (pH 7.5), 1 mM DTT, 10% glycerol, 1 mM GTP-Mg2+, 
and indicated amount of KCl at specified temperatures. Splicing products were 
analyzed in either a 4% or 6% denaturing polyacrylamide gel that was dried and 
quantified with a Storm PhosphorImager (GE Bioscience). For peptide 
complementation experiments, indicated amounts of H0-WT or truncated H0 peptides 
were incubated with the CYT-18/Δ33−61 protein at 25 °C for 1 hour (h) before being 




indicated amounts of CYT-18 protein with a 2-fold molar excess of 32P-labeled RNA 
substrate in the described splicing conditions lacking GTP-Mg2+. These reactions 
were initiated by addition of 1 mM GTP-Mg2+. 
2.6 RNA equilibrium binding assay 
25 µL reactions were set up as described in the group I intron splicing and 
peptide complementation assays with GTP omitted. After incubating for 1 h at 25°C, 
within a 96-well vacuum manifold (Schleicher & Schuell), 5 µL of each reaction was 
spotted directly on to layered nitrocellulose (0.2 µm pore size; Invitrogen) and nylon 
(Hybond-N; Amersham) membranes that were presoaked in the splicing buffer with 
50 mM KCl. The membranes were washed three times with 250 µL of the same 
splicing buffer, dried and then quantified with a Storm PhosphorImager. The 
disintegrations per minute (DPM) values on nitrocellulose membrane were divided by 
the sum of DPM values from both the nitrocellulose and nylon membranes. The 
calculated percentages of the protein-bound 32P RNA out of the total 32P RNA input 





Chapter 3: Functional Assays and Stability of CYT-18/Δ33−61 
3.1 The first mutant of CYT-18 with a complete H0 deletion 
As described in Chapter 1, the previous CYT-18 N-terminal truncations 
constructed to study H0 (residues 33-61) all began after Phe37.38, 40 In order to further 
examine the role of the CYT-18-specific H0 insertion, and develop a peptide 
complementation assay, I constructed the first mutant of CYT-18 with a complete H0 
deletion (Figure 3.1). This mutant (CYT-18/Δ33−61) was generated through addition 
of an N-terminal hexahistidine tag followed by a protease cleavage site (Chapter 2). 
Immobilized metal affinity purification steps before and after removal of the 6XHis 
tag with TEV protease yielded > 95% pure protein (judged by the Coomassie stained 
SDS-PAGE gel, Figure 3.2) with native Gly62 as the N-terminal-most residue. The 
purification method as described in Chapter 2 via a Ni2+ column, TEV cleavage, and a 
second Ni2+ column enabled me to maintain high monovalent salt and glycerol 














Figure 3.1 - CYT-18 protein and peptide sequences.  
(A) The N-terminus of the mature CYT-18 proteins used in this study. Residues 1-32 
of CYT-18 are the mt localization peptide and are cleaved upon entry into the mt 
matrix. Met32 in the wild-type CYT-18 construct is present as a result of translation 
initiation of this construct. Residues 33-61 comprise the H0 N-terminal extension. 



















Figure 3.2 - SDS-PAGE result for purified CYT-18 and CYT-18/Δ33−61 
proteins. 
The purification methods for CYT-18 and CYT-18/Δ33−61 yielded > 95% pure 




3.2 Tyrosyl-adenylation activity and protein stability 
Tyrosyl adenylation assays were utilized to assess the activity of CYT-
18/Δ33−61. Comparison of tyrosyl adenylation activity between A280-normalized 
wild-type CYT-18 and CYT-18/Δ33−61 showed little or no reduction in activity 
immediately after protein purification (Figure 3.3A). However, both previous 
studies40 and the observations from this work indicated that the N-terminally 
truncated CYT-18 was less stable than the wild-type protein, presumably due to the 
solvent exposure of the hydrophobic H0 binding site on the core of the protein. The 
overall stability of the wild-type and truncated proteins were assessed by comparing 
their behaviors to urea denaturation/renaturation (Figure 3.3A). For wild-type CYT-
18, ~50% of the input protein was recovered based on A280 following renaturation, 
with the final tyrosyl-adenylation activity nearly identical to that of the non-denatured 
sample. For CYT-18/Δ33−61, only 15% of the total input protein was recovered with 
only 13% of the wild-type activity. The significant difference in both recovery and 
activity has suggested that H0 plays an important role in maintaining an active protein 
conformation.  
To know if H0 is able to stabilize CYT-18/Δ33−61 during renaturation, 6-fold 
molar excess of H0-WT with respect to the initial concentration of CYT-18/Δ33−61 
was added during renaturation. After the renaturation, CYT-18/Δ33−61 was 
incubated with 6-fold molar excess of H0-WT at either 37 °C or room temperature for 
30 min, before its concentration was normalized with respect to the wild-type CYT-
18. The tyrosyl-adenylation result (Figure 3.3B) shows that the addition of H0-WT 











Figure 3.3 - Tyrosyl-adenylation assays for renatured proteins.  
The graphs show the amount of filter-bound 3H-tyrosyl-adenylate for CYT-18 and 
CYT-18/Δ33−61 (ΔH0) relative to wild-type CYT-18 prior to denaturation. Proteins 
were denatured in solution containing 8M urea and renatured by dilution and 
concentration without (A) or with (B) 6-fold molar excess of H0-WT. Values are the 







3.3 Group I intron splicing 
Based on the observed low stability of CYT-18/Δ33−61, I examined its ability 
to splice group I introns at three different temperatures. Consistent with previous 
results for other N-terminally truncated CYT-18 proteins, CYT-18/Δ33−61 has little 
detectable specific ND1 intron splicing at 37 °C after 60 min (Figure 3.4A). 
However, ND1 splicing was readily detectable at 25 °C and 30 °C, though 
significantly decreased from the wild-type CYT-18 at these two temperatures. One 
major lower molecular weight RNA product was observed only in the presence of the 
truncated protein and was more prominent with increased temperature. This aberrant 
RNA product was discrete and observed from multiple protein and RNA substrate 
preparations but did not dependent on the addition of exogenous guanosine (Figure 
3.5). This result suggests that the aberrant RNA product may be the result of a 
specific interaction formed readily in the absence of H0 that facilitates phosphodiester 
backbone cleavage. Previous assays demonstrated that N-terminally truncated CYT-
18 was capable of splicing the N. crassa mt LSU intron.40 Consistent with these 
findings, CYT-18/Δ33−61 was capable of splicing the mt LSU intron at both 25 and 
30 °C, though with reduced activities compared to the wild-type CYT-18 (Figure 
3.4B). Similar to the previous study40, CYT-18/Δ33−61 showed detectable but 
significantly decreased splicing activity at 37 °C. This had been previously attributed 
to decreased protein stability for the N-terminal truncation and was consistent with 
the stability results. At all temperatures tested, there was a greater accumulation of mt 




comparison to previous studies40. This is likely due to the less stringent monovalent 







Figure 3.4 - Comparison of CYT-18 and CYT-18/Δ33−61 group I intron splicing 
activity.  
Splicing was performed at 50 mM KCl at three temperatures for two N. crassa group 
I introns: (A) the ND1 intron and (B) the mt LSU intron. Products shown are 
following 60 min incubation at the given temperature. Final precursor RNA and 
protein dimer concentrations were 200 nM and 800 nM, respectively. A sample with 
no protein (NP) is shown for each temperature. Percentages of the final RNA 
products are shown to the right of each product. Splicing intermediates were 
quantified as a single band. P: Precursor RNA, I: spliced intron, E1-I: 5’ exon-intron, 
I-E2: intron-3’ exon intermediate, E1-E2: ligated exons, A: aberrant RNA product. 





















Figure 3.5 - CYT-18/Δ33−61 group I intron splicing without GTP.  
200 nM ND1 intron was incubated under modified splicing conditions (no GTP) with 
800 nM CYT-18/Δ33−61 (ΔH0) dimer. The incubation was performed with 50 mM 
KCl at three temperatures. Three time points (5’, 30’, 60’) are shown under each 
temperature. Percentages of RNA products at 60’ are shown to the right of each 





Chapter 4: Peptide Complementation by H0-WT 
4.1 Overview 
The previous structural study showed that H0 is stabilized against the rest of 
CYT-18 primarily through two hydrophobic interactions.39 The critical nature of 
these interactions was suggested by genetic experiments, which showed the involved 
H0 residues are either invariant or highly conserved in splicing-competent CYT-18 
mutants isolated from protein libraries in which portions of H0 were partially 
randomized.40 The first interaction involves Trp52 and Arg55 from the middle portion 
of H0, whose side chains stack with Arg95 from the protein. The second interaction 
involves Ile58 from the C-terminal portion of H0, which interacts with residues in H2 
from the protein. To quickly examine how different H0 mutants might affect group I 
intron splicing, I developed a peptide complementation assay. The full-length H0 
peptide (H0-WT), or derivatives (H0-37, H0-42, and H0-46), was incubated with 
CYT-18/Δ33−61, and the reconstituted protein was tested for intron splicing at 
various concentrations, temperatures, and monovalent salt concentrations. 
4.2 Temperature and salt dependence 
Figure 4.1 shows CYT-18/Δ33−61’s ability to splice the ND1 intron in the 
presence of 2-fold molar excess H0-WT peptide (with respect to the protein 
monomer), at three different temperatures and monovalent salt concentrations. The 
addition of the peptide enhanced the splicing activity of the CYT-18/Δ33−61 at all 
temperatures, with the greatest enhancement at 30 °C and at the two lowest salt 




activity at 50 mM KCl, while maximum splicing stimulation was observed at 25 mM 
KCl at 37 °C. For all temperatures tested, the amount of aberrant product was reduced 
in the presence of the peptide, though it was present to a greater extent at both 
elevated salt and temperatures. The reconstituted protein did not enhance splicing of 









Figure 4.1 - Peptide complementation by H0-WT.  
200 nM ND1 intron was incubated under described splicing conditions with 800 nM 
CYT-18/Δ33−61 (ΔH0) dimer alone or reconstituted with 3200 nM H0-WT peptide 
(ΔH0 + H0). Splicing with the reconstituted protein was performed at the three 
temperatures and four monovalent salt concentrations indicated. Three time points 
(5’, 30’, 60’) are shown for each sample. Percentages of RNA products at 60’ are 























Figure 4.2 - N. crassa mt LSU intron splicing with H0-WT peptide 
complementation.  
These results compare splicing of CYT-18/Δ33−61 alone or when reconstituted with 
2-fold molar excess H0-WT peptide. Splicing assays were performed at 50 mM KCl 
as described in the main text. The percent precursor (P), and spliced intron (I) are 





4.3 Concentration dependence 
Previous studies indicated marked protein concentration dependence for CYT-
18 intron splicing when N- and C-terminal truncations were used.40 To examine if this 
was also true with CYT-18/Δ33−61, I performed ND1 burst splicing at two different 
protein concentrations with the RNA substrate in excess at 25 °C. The results are 
shown in Figure 4.3. CYT-18/Δ33−61 splicing in the absence of the H0-WT peptide 
was virtually identical at both the high and low protein concentrations with the 
precursor RNA disappearing linearly with time. Both wild-type CYT-18 and the 
reconstituted protein showed biphasic disappearance of the RNA precursor, with a 
greater extent of splicing in the initial phase at the higher protein concentration. At 
the lower protein concentration, the wild-type CYT-18 initial rate was 3.5 fold faster 
than the reconstituted protein (2.8 vs. 0.8 × 10−3 s−1), but the rates were comparable 
(2.3 vs. 1.9 × 10−3 s−1) at the higher protein concentration, indicating that the 
reconstituted protein at this concentration was nearly as active as the wild-type. This 
suggests that the reconstituted protein is functionally equivalent to the wild-type 
CYT-18 for splicing ND1 intron. Because the peptide/dimer ratio was maintained at 
2:1, the decreased splicing at the lower protein concentration could also reflect 









Figure 4.3 - Concentration dependence of CYT-18/Δ33−61 complementation by 
H0-WT. 
Burst splicing reactions with precursor RNA in 2-fold molar excess to protein dimer 
were carried out at (A) 500 nM protein dimer and (B) 25 nM protein dimer. H0-WT 
peptide was maintained at 2-fold molar excess to the CYT-18/Δ33−61 (ΔH0) dimer 
concentration. H0-WT used in these experiments was produced recombinantly (see 
Chapter 2). kobs for the two phases of splicing are shown with the amount of spliced 





4.4 H0 stoichiometry 
The CYT-18/intron co-crystal structure suggested that the N-terminal 
insertions from just one of the dimer subunits were responsible for a majority of the 
intron contacts, with H0 from the other subunit in proximity to the intron’s P5 loop.30 
Using the H0 peptide complementation assay and burst kinetic analysis, the necessary 
stoichiometry of H0 for intron splicing was explored. Using multiple CYT-18 protein 
concentrations (500, 750, and 1000 nM CYT-18 monomer), the ability of the H0-WT 
peptide to stimulate CYT-18/Δ33−61 splicing at ratios from 1:50 to 4:1 
peptide/protein monomer was examined. Figure 4.4 shows the percent spliced ND1 
intron (relative to all RNA bands) versus the ratio of peptide to protein monomer after 
10 min, a time point determined to be within the initial burst phase for the 
reconstituted protein. At all protein concentrations, the appearance of intron increased 
with the addition of peptide until reaching a peak at a peptide/monomer ratio of 1:2. 
Surprisingly, for 500 and 750 nM protein monomer, a drop was observed in the 
appearance of intron RNA at the 1:1 ratio. This decrease was not readily explainable 
but was observed in multiple independent experiments. In contrast, at 1000 nM CYT-
18, there was a slight increase at the 1:1 ratio, though this was within error of 
measurements taken at 1:2 and 2:1. At all protein concentrations, the plateau was re-
established at ratios of 2:1 or higher. These results indicate that single H0-WT peptide 











Figure 4.4 - H0 stoichiometry.  
The indicated concentrations of CYT-18/Δ33−61 monomer were titrated with 
increasing concentration of H0-WT peptide prior to initiating the burst splicing 
reaction with precursor RNA in 2-fold molar excess to protein dimer. The percent 
intron product was determined at the 10 min time point and plotted against the molar 
ratio of peptide to CYT-18/Δ33−61 monomer. Points are the mean from three 





Chapter 5: The Five N-Terminal H0 Residues Are Required for 
Efficient Intron Splicing 
5.1 Truncated H0 peptides fail to trans-activate splicing 
The H0 peptide complementation assay was developed to provide a rapid way 
of exploring how modified H0 peptides can impact group I intron splicing. Three 
different N-terminally truncated H0 peptides (H0-37, H0-42, and H0-46; Figure 
3.1B) were examined. H0-WT and all three truncated peptides had similar spectra in 
circular dichroism measurements (Figure 5.1), indicating that there were no major 
structural differences in solution. Surprisingly, when used in the peptide 
complementation assay, none of the truncated peptides were capable of significantly 
stimulating CYT-18/Δ33−61’s ND1 intron splicing activity (Figure 5.2A). The lack 
of splicing could be the result of the peptides not binding to the truncated protein or 
their inability to productively contact the intron RNA when bound to CYT-
18/Δ33−61. Competition assays using 3-fold molar excess of the truncated peptides to 
H0-WT revealed little (H0-42) or no (H0-37, H0-46) reduction in H0-WT’s ability to 
trans-activate CYT-18/Δ33−61’s splicing activity (Figure 5.2B).  
The inability for even the shortest N-terminal peptide truncations to bind or 
stimulate splicing in the peptide complementation assay indicated for the first time 
that these residues might have an important functional role in intron splicing. To 
compare how short N-terminal truncation might differ between the peptide 
complementation experiments and a truncated recombinant CYT-18, CYT-




protein did not have the stability issues observed with CYT-18/Δ33−61 and behaved 
identically to wild-type CYT-18 in tyrosyl adenylation assays (Figure 5.3). However, 
consistent with observations from the peptide complementation assays, this N-
terminally truncated protein had significantly reduced splicing activity for the ND1 
intron at 50 mM KCl at all three temperatures tested (Figure 5.4A). The aberrant 
splicing product was also present at levels comparable to CYT-18/Δ32−61 at 37 °C. 
Interestingly, the CYT-18/Δ33−37 also showed reduced splicing activity for the mt 
LSU intron when compared to wild-type CYT-18 (Figure 5.4B). Together, these 
results indicate that the N-terminal most residues of CYT-18 play a role in splicing 











Figure 5.1 - Background-subtracted circular dichroism spectra of the peptides 
used in this study.  
Circular dichroism experiments were done with H0-WT and truncated H0 peptides in 
10 mM Tris-HCl (pH 7.5) and 10 mM KCl. The peptide concentration was adjusted 
to 12 µM based on A280 and analyzed by Jasco J-810 spectropolarimeter. The 














Figure 5.2 - Peptide complementation with truncated H0 peptides.  
(A) Burst splicing time courses using 500 nM dimeric CYT-18 (WT), CYT-
18/Δ33−61 (ΔH0) alone, and with equimolar H0 peptides to protein monomer. (B) 
Truncated peptide competition experiments. 500 nM CYT-18/Δ33−61 dimer was 
incubated with peptide mixtures containing 1 µM H0-WT and 3 µM N-terminally 
truncated H0 peptide. H0-WT used in these experiments was produced recombinantly 




















Figure 5.3 - Tyrosyl-adenylation assays for CYT-18/Δ33−37.  
The graph shows the amount of filter-bound 3H-tyrosyl-adenylate for CYT-18, CYT-
18/Δ33-37 (Δ33−37), and CYT-18/Δ33−61 (ΔH0). Values are the mean for 6 
















Figure 5.4 - CYT-18/Δ33−37 group I intron splicing.  
Splicing was performed at 50 mM KCl at three temperatures for two N. crassa group 
I introns: (A) the ND1 intron and (B) the mt LSU intron. All products shown are 
following 60 min incubation at the given temperature. Products are labeled and 




5.2 RNA equilibrium binding assay  
In order to know if the trans-activation of CYT-18/Δ33−61’s splicing activity 
by H0 complementation is due to an improved protein/RNA binding, and to know if 
the five N-terminal-most residues are important to CYT-18/RNA binding, I 
performed N. crassa ND1 intron RNA equilibrium binding assay with the 
reconstituted protein of CYT-18/Δ33−61 and H0 peptides (2-fold molar excess with 
respect to the protein monomer), and CYT-18/Δ33−37 (Figure 5.5).  
The normalized binding percentage (with respect to wild-type CYT-18) has 
improved from 13% for CYT-18/Δ33−61 alone to 40% for the reconstituted protein 
(CYT-18/Δ33−61 and H0-WT). Since the improvement in protein/RNA binding is 
~25% lower than the improvement in ND1 splicing observed in the peptide 
complementation by H0-WT  (52% increase under the same condition), I reasoned 
that apart from assisting in protein/RNA binding, H0-WT also stabilizes CYT-
18/Δ33−61 by minimizing protein aggregation caused by non-native hydrophobic 
interactions. In agreement with the other peptide complementation results, the N-
terminally truncated H0 peptides all failed to significantly improve the ND1 intron 
binding of CYT-18/Δ33−61. The failure to improve RNA binding accounts for the 
inability of the N-terminally truncated H0 peptides to trans-activate CYT-
18/Δ33−61’s ND1 splicing activity. However, CYT-18/Δ33−37 showed a similar 
RNA binding percentage as the wild-type CYT-18, suggesting that the five N-
terminal-most residues are dispensable for CYT-18/ND1 intron binding. The RNA 
equilibrium binding assays provide information on how peptide complementation by 




is attributed to the improvement of protein/RNA binding and possibly the improved 







Figure 5.5 - RNA equilibrium binding assay for N. crassa ND1 intron 
The normalized binding percentages indicate the ratios of protein-bound 32P RNA out 





5.3 Crystal structure re-evaluation  
The importance of H0’s five N-terminal-most residues for ND1 splicing in the 
context of both the full-length protein and the peptide complementation splicing led 
me to re-examine the CYT-18/Δ424−669 crystal structure for structural clues to their 
function. Despite weak electron density, these residues were successfully built using 
the original data by my laboratory, now guided in part by the contiguous backbone 
density in the co-crystal structure15 (Figure 5.6 and Figure 5.7A). Along with the 
addition of the N-terminal residues, several side chains were successful added, which 
had been omitted from the H0 helix (Glu47, Glu49) resulting in an overall reduction 
in Rfree and improved model geometry (Table 5.1). The backbone density was 
reasonably well-defined for residues 33−38, while the side chain density varied. 
Significantly, Arg34 and Arg35 had the most well-defined side chains. The refined 
structure showed that Arg35 makes a potential salt bridge with Glu296 from Ins2 
(Figure 5.6B and Figure 5.7B) and Arg34 makes a potential salt bridge with Glu49 
from the H0 α-helix while also making potential hydrogen bonding contacts with 










Figure 5.6 - Structural evidence for ionic interactions by H0 N-terminal residues.  
(A) 2m|Fo| − D|Fc| electron density contoured at 1.0σ around H0 and Ins2 amino 
acids. H0 residues shown in yellow are newly built residues using the original CYT-
18/Δ424−669 crystal structure data. (B) and (C) show the potential ionic interactions 












Figure 5.7 - CYT-18 co-crystal structure.  
(A) Contiguous electron density between H0 and Ins2 (cyan). RNA structural 
elements (green, grey) in proximity to H0 and Insertion 2 (P7, P9) are labeled. (B) 
Superposition of the CYT-18 co-crystal structure and the newly refined CYT-







Table 5.1 - Comparative refinement statistics  
 
 Original refinement New refinement 
Refinement   
Resolution (Å) 20-1.95 58.6-1.95 
Rwork / Rfree 17.4/23.5 16.7/21.1 
R.m.s deviations   
Bond lengths (Å) 0.018 0.007 
Bond angles (°) 1.621 1.127 





Chapter 6:  Summary and Discussion 
 
6.1 Only one H0 insertion of the CYT-18 homodimer is required for splicing 
The peptide complementation assay developed has allowed me to address 
several major questions not fully explained by previous biochemical or structural 
information. First, this work has been able to address if both H0 insertions of the 
homodimer are required for splicing. Understanding the different roles of the two 
CYT-18 subunits in splicing has been challenging due to the difficulty of creating and 
purifying heterodimeric CYT-18. The CYT-18/Twort intron co-crystal structure 
established that H0 from one subunit was responsible for contacting the intron RNA 
directly, but the close proximity of H0 from the other subunit to the P5 region of the 
RNA,15 as well as site-directly hydroxyl cleavage data that placed H0 residues near 
P539 suggested that H0 insertions from both subunits may be involved in splicing. By 
controlling the relative concentrations of the H0 peptide and CYT-18 protein, this 
work demonstrated over a range of protein and peptide concentrations that ND1 
splicing reaches a plateau when a maximum of 50% of the H0 binding site could be 
occupied. This strongly suggests that only a single H0 peptide is necessary for 
productive splicing. If the second H0 contacts the intron RNA, these interactions are 
not required for establishing a splicing-active intron conformation. It remains unclear 
why a drop in splicing activity was observed at equimolar concentrations of peptide 
to protein monomer at certain protein concentrations, though this may be related to 
concentration dependence observed in Figure 4.3. The drop in activity might imply 
negative cooperativity, though it is not clear why the activity would increase with the 




second peptide induces a local asymmetry in the protein dimer that negatively affects 
splicing. This subtle negative cooperativity could therefore be observed most 
prominently at or near conditions of peptide saturation. CYT-18 and bacterial 
TyrRS’s all display half-of-sites reactivity in tRNA charging, which is thought to be 
an extreme case of negative cooperativity induced by dimer asymmetry.42 
6.2 CYT-18’s N-terminal-most residues play an important role in intron splicing 
 The peptide complementation assay has also provided the first evidence that 
the N-terminal-most residues play an important role in intron splicing. The CYT-
18/Δ424−669 crystal structure suggested that a majority of the contacts between H0 
and the rest of CYT-18 were through hydrophobic interactions.39 Based on this 
information, I reasoned that the N-terminally truncated H0 peptides that retained 
those hydrophobic interactions would bind to CYT-18/Δ33−61 nearly as well as the 
H0-WT peptide. Because only the N-terminus of H0’ s α-helical region was found to 
contact the Twort intron in the co-crystal structure, the initial anticipation was that 
only peptides shortened beyond Pro39 would fail to complement splicing and that 
these peptides might function as competitive inhibitors of H0-WT complementation. 
The inability of the truncated peptides, including H0-37 which retained the entire α-
helical sequence, to efficiently complement splicing or compete with H0-WT for 
complementation is consistent with the truncated peptides being unable to efficiently 
bind the protein at the H0 binding site, despite the peptides having all of the 
hydrophobic residues that make up a bulk of the interaction surface with the TyrRS 




present in H0-WT but absent in H0-37 must interact with either another part of the 
protein or the intron RNA to enhance peptide binding. 
Splicing with the CYT-18/Δ33−37 protein showed significantly reduced 
splicing activity for both the ND1 and mt LSU introns, indicating that these first five 
residues are important for splicing in the context of the full-length protein and not just 
for peptide binding in the complementation assay. Further, CYT-18/Δ33−61 and 
CYT-18/Δ33−37 showed similar reduced mt LSU splicing activity in comparison to 
wild-type CYT-18 at all temperatures tested. Because CYT-18/Δ33−37 did not 
exhibit the same issues with solubility, the decreased mt LSU splicing activity for 
these and other N-terminal truncations is not likely due entirely to decreased protein 
stability as was previously ascribed.40 
6.3 Key ionic interactions are suggested between H0 residues and Ins2  
The peptide complementation assay has also provided initial evidence for how 
these residues may be functioning in the full-length protein. The H0-WT peptide 
showed a decreased ability to complement splicing at elevated monovalent salt and 
temperature. The CYT-18/group I intron interaction itself is salt dependent,25, 27, 30 
and the salt-dependent complementation could simply reflect a decrease in intron 
affinity. However, previous studies indicated that binding and splicing were reduced 
only at KCl concentrations greater than 100 mM at 37 °C.25, 27 Because this is a 
tripartite system, the decrease in activity may also be due to decreased peptide affinity 
at higher salt and temperature, implicating ionic interactions. 
Several other lines of analysis suggest that charged residues in the H0 N-




interaction in the CYT-18/Δ424−669 crystal structure has been successfully 
visualized. The missing N-terminal residues were successfully built to show that 
Arg35 makes a potential salt bridge with Glu296 from Ins2. Previous biochemical 
data had implicated Glu296 and surrounding residues as being important in intron 
splicing. A short Ins2 deletion mutant that removed Glu296 inhibited ND1 intron 
splicing activity.39 The importance of this interaction is also evident from sequence 
analysis of Pezizomycotina mt TyrRS’s30. Arg35 is highly conserved in the 
Pezizomycotina mt TyrRS’s (15 of 18 species). One of these exceptions, 
Stagansopora nodorum, is believed to have lost its intron splicing activity30, 43, while 
another, Podopspora anserina, contains tandem lysine residues just N-terminal of the 
Arg34 position. Only the mt TyrRS from Magnaporthe grisea appears to lack basic 
residues at the H0 N-terminus30. Previous sequence analysis revealed that Ins2 of 
Pezizomycotina mt TyrRS’s lacked significant positional sequence conservation, but 
compositionally these insertions contained a large number of prolines and acidic 
residues.30 Overall, these mt TyrRS’s average 4 acidic residues in this 18 amino acid 
insertion, though notably the M. grisea mt TyrRS contains the fewest number of 
acidic residues with only two. The conserved charge distribution between the H0 N-
terminus and Ins2 suggests an evolutionary conservation of ionic interactions between 
H0 and Ins2. 
6.4 H0 serves as an important structural link connecting the N-terminal splicing 
insertions of CYT-18. 
The CYT-18/group I intron complex has been a unique system for 




related RNA substrates.30, 39, 44 My study largely supports these previous results but 
hints at greater complexity. Previous structural information on CYT-18 showed that 
H0 makes side chain contacts with Ins1. This study establishes that H0 also interacts 
with Ins2, placing H0 in contact with both of the other N-terminal splicing insertions. 
It had been previously suggested that the role of H0 in splicing the mt LSU intron was 
primarily to stabilize another region of the protein that directly contacted the intron 
RNA.40 This analysis can be explained by my results that suggest that the salt bridge 
between H0’ s N-terminal residues and Ins2 may be important for establishing the 
relative orientation of H0 and Ins2 during splicing. Thus, even if H0 does not directly 
contact some group I introns, it may still be important in helping to stabilize or 
position Ins1 and Ins2. 
The development of a peptide complementation assay has allowed me to gain 
further insight into H0’ s role in group I intron splicing. My results indicate that H0 
serves as an important structural link that connects the N-terminal splicing insertions 
of CYT-18. It has been previously suggested that the highly specific structural 
features of the mt TyrRS splicing adaptations make them potentially unique targets 
for the development of antifungal drugs for Pezizomycotina species30 such as 
Histoplasma capsulatum, Coccidiodies sp., and Aspergillus sp. This study has 
elucidated a new role for H0’ s N-terminal residues, further highlighting it as a 
potentially targetable feature for drug development. Importantly, this H0 peptide 
complementation has been demonstrated capable of uncovering important features 




in assessing small molecule inhibitors that could target mt TyrRS N-terminal 
insertions. 
6.5 Contributions to present knowledge and future implications 
The peptide complementation assay has allowed me to address several major 
questions not fully explained by previous studies. First, this work has been able to 
address if both H0 insertions of the homodimer are required for splicing. I have 
demonstrated only one H0 insertion of CYT-18 is required for productive splicing. 
This assay has also provided the first evidence that the N-terminal-most residues play 
an important role in intron splicing, which led to the finding of H0’s new role as a 
structural link connecting all three N-terminal insertions to help maintain their 
relative positions for productive intron binding.  
Since the expression of many fungal mt genes require proper splicing of group 
I introns, suppressed group I intron splicing of these genes will result in a lack of 
mature RNAs that leads to a suppressed mt gene expression. The insufficient mt gene 
expression will further suppress cellular respiration, which exerts detrimental effects 
on the obligate aerobic fungal organism. For instance, in the mt of N. crassa, failure 
to splice ND1 intron will suppress gene expression of NADH dehydrogenase, causing 
a suppressed oxidation phosphorylation in mt. In addition, failure to splice mt LSU 
intron will cause a suppressed mt ribosome assembly, largely affecting the mt protein 
translation. 
Like other mt proteins that are expressed from nuclear genes, CYT-18 is 
translated in cytosol and retained unfolded with the aid of the cytosolic chaperones. 




matrix. After cleavage of the N-terminal mt targeting sequence, the unfolded CYT-18 
folds presumably with aid of the mt chaperones. The partially folded CYT-18 protein 
during the folding process can be a good candidate for antifungal drug target. Since 
H0 becomes the N-terminal extension of CYT-18 following the cleavage of the N-
terminal mt targeting sequence, it presumably folds in last after the mt TyrRS core is 
fully folded. Based on these analyses and that H0 in a fully folded CYT-18 is 
important to the group I intron splicing, researchers can potentially use small 
molecule drugs that could competitively bind to the H0 binding site on the mt TyrRS 
core during the last step of protein folding. By competitively and exclusively 
occupying the H0 binding site and prohibiting formation of a completely folded and 
splicing-competent CYT-18 with a properly folded H0, the small molecule drugs can 
suppress the mt group I intron splicing and essential mt gene expression, which will 
suppress the cellular respiration and exert detrimental effects to the obligate aerobic 
fungal organism. 
Therefore, a major future direction of this work is to use the developed 
peptide complementation assay as a key tool in assessing small molecule inhibitors 
that could target mt TyrRS N-terminal insertions. By rapidly screening numerous 
small molecule inhibitors from the drug libraries built by in silico screening and yeast 
cell biological experiments, researchers should be able to quickly discover potent 
drug candidates that are featured by high and specific binding affinity to the H0 





PART II: THREE-DIMENSIONAL DNA CRYSTALS AS 
VEHICLES FOR BIOCATALYSIS 
 
Chapter 7:  Introduction 
 
7.1 Goals of DNA nanotechnology  
DNA has proved to be a successful material for the self-assembly of nano-
scale structures in two and three dimensions because of its inherent programmability 
and predictable structural features.45-54 One of the original55 and ongoing goals of the 
DNA nanotechnology field has been the rational design of periodic three-dimensional 
DNA arrays, or crystals.56, 57 DNA crystals have been envisioned as self-assembling 
porous solids that could be used as molecular scaffolds for the structure determination 
of proteins, as templates for 3D molecular electronics,58 or as zeolite-like materials 
for separations and catalysis.59 Such crystals were originally designed to serve as 3D 
scaffolds that tether molecules of a guest protein at specific locations and 
orientations, thus the protein structure could be determined as part of the DNA 
lattice.55 If implemented correctly, this approach could bypass the crystallization 
problem for difficult-to-crystallize, but pharmaceutically significant proteins. 
7.2 Rationally designed 3D DNA crystals with a non-Watson-Crick motif  
The DNA crystals used in this study originate from a previously reported 3D 
DNA crystal structure.60 The original structure was the first reported continuously 
base-paired 3D DNA lattice, which was self-assembled into a 3D crystalline array 
from a DNA 13-mer oligonucleotide (PDB ID: 1P1Y).60 In contrast to other DNA 




base-parings.60 The non-canonical base-pairings function as branches connecting the 
linear Watson-Crick duplexes into a periodic 3D assembly.  This non-Watson-Crick 
motif was demonstrated to be predictable and could be used to rationally design DNA 
crystals with expanded lattice dimensions that self-assemble in the presence of 
divalent cations.60  
The DNA crystals (Figure 7.1A) used in this study were designed to have 
expanded solvent channels that run through the length of the crystals.60 Down the six-
fold crystallographic symmetry axis, these channels are ~9 nm in diameter (Figure 
7.1B) and previous work61 showed that proteins with molecular weights (MW) of 14-
45 kDa could be incorporated into these channels, while larger proteins were 
excluded from the crystal interior. Based on these observations, development of a 
DNA crystal-based enzyme container for biocatalysis is possible. The activity of 
enzymes encapsulated within the crystals’ solvent channels can be examined, while 
the activity from any enzyme free in solution is inhibited by recombinant enzyme 
inhibitor (MW > 45 kDa) that is excluded from the crystal interior. This study shows 
that protein enzymes encapsulated in the solvent channels of a DNA crystal are 
capable of performing catalysis. The kinetic properties of these encapsulated enzymes 
have features consistent with other immobilized enzymes,62-67 and represent a solid-














Figure 7.1 - Three-dimensional DNA crystals.  
(A) Image of a representative crystal used in this study from light microscopy. (B) 







7.3 Immobilization methods of enzymes and mass-transfer effects 
Aiming at improved stability and easiness of separation/recycling from the 
reaction media, numerous immobilization methods of enzymes have been developed 
following six decades of extensive exploration.64, 68, 69 The immobilization methods 
range from binding to carrier to cross-linked enzyme crystals or lyophilized 
powders.64, 69 However, for most of these methods, physical restriction of the enzyme 
mobility caused by enzyme immobilization affects the solute mobility, which is 
referred to as mass-transfer effect. Among the immobilization methods of enzymes, 
most, if not all are subject to mass-transfer effects, which generate substrate or pH 
gradients that change the enzymatic rates. Since the 3D DNA crystals used in this 
study also restrict the mobility of enzymes by encapsulation, the crystal-encapsulated 
enzymes would very likely show enzymatic kinetics different from aqueous enzyme 






Chapter 8: Experimental Procedures  
8.1 Expression and purification of recombinant MBP-tagged RNase inhibitor 
The porcine RNase inhibitor open reading frame70 (a generous gift of Prof. 
Jan Hofsteenge, Friedrich Miescher Institute, Basel) was cloned into vector pMAL-
C2T, verified by sequencing using malE primer, and expressed using autoinduction in 
E. coli HMS174(DE3) cell. The MBP fusion protein was purified by amylose affinity 
chromatography. Inhibitor activity was assayed in the following mixture with a 
Perkin-Elmer fluorometer (λexcit = 478 nm; λemis = 522 nm): 0.63 µM RNA substrate; 
0-200 µM RNase A; 10 mM sodium cacodylate (NaCaco) pH 7.0; 120 mM 
magnesium formate (Mg(HCO2)2); and 50 mM lithium chloride (LiCl). 
8.2 DNA crystallization 
Individual DNA strands (Figure 8.1) were synthesized by standard 
phosphoramidite chemistry, purified by denaturing polyacrylamide electrophoresis 
followed by electroelution, desalted by using dialysis, and concentrated in a vacuum 
concentrator. The assembly strand and spacer strand were mixed in a 1:1.1 ratio and 
the final concentrations were adjusted to 0.21 mM. Crystals were grown in sitting-
drop vapor diffusion trays by mixing 2 µL of the DNA solution with 2 µL of the well 
solution (120 mM Mg(HCO2)2, 50 mM LiCl, and 10% 2-methyl-2-4-pentanediol) and 
incubating at 37 °C overnight before gradually cooling to 22 °C at a rate of 1 °C/15 


















Figure 8.1 – Sequences for the DNA oligonucleotides used in this study. 
Crystals generated from EX11 (assembly strand) and EET11 (spacer strand) were 
used for some of the direct fluorometry assay described below. Crystals generated 
from EX11rodtrial1 (assembly strand) and EET11rodtrial1 (spacer strand) were used 





8.3 RNase A incorporation and protein coating of a DNA crystal 
RNase A was incorporated through diffusing by transferring a single DNA 
crystal into RNase A soaking buffer (44 mg/mL bovine pancreatic RNase A, 10 mM 
NaCaco pH 7.0, 120 mM Mg(HCO2)2, and 50 mM LiCl) and incubating at 4 °C for 4 
days. Protein coating was performed after the RNase A-infused DNA crystal was 
washed by soaking twice in 200 µL MFJ buffer (10 mM NaCaco pH 7.0, 120 mM 
Mg(HCO2)2, and 50 mM LiCl), followed by removal of 100 µL of solution and 
addition of 100 µL fresh MFJ buffer three times. For coated crystals, the washed 
RNase A-infused DNA crystal was transferred into hen egg-white lysozyme soaking 
buffer (30 mg/mL lysozyme, 10 mM NaCaco pH 7.0, 120 mM Mg(HCO2)2, and 50 
mM LiCl) and incubated for 5 min. The crystal was then transferred to cross-linking 
buffer (2% fresh glutaraldehyde, 10 mM NaCaco, pH 7.0, 120 mM Mg(HCO2)2, and 
50 mM LiCl) and incubated for 30 min. The crystal was washed again and incubated 
with RNase inhibitor or MBP-RNase inhibitor for at least 10 min before the activity 
assay. All activity assays also included excessive MBP-RNase inhibitor in the 
reaction conditions. All routine washing and protein coating steps were performed at 
room temperature. 
8.4 Fluorescence measurements and reusability experiment 
Direct fluorescence measurements were carried out by transferring an RNase 
A-infused DNA crystal into 120 µL reaction buffer (4-fold molar excess of RNase 
inhibitor or MBP-RNase inhibitor, 10 mM NaCaco pH 7.0, 120 mM Mg(HCO2)2, and 
50 mM LiCl) in a cuvette. Fluorescence intensity was monitored (λexcit = 475 nm; 




to a final concentration of 0.63 µM. Indirect fluorescence measurements were carried 
out by transferring an RNase A-infused DNA crystal into 400 µL reaction solution 
(0.63 µM RNA substrate, 4-folds excess of MBP-RNase inhibitor, 10 mM NaCaco 
pH 7.0, 120 mM Mg(HCO2)2, and 50 mM LiCl). 60 µL (enzymatic kinetics 
measurement) or 120 µL (reusability test) reaction buffer was taken at different time 
points. For the reusability experiment, the crystal was washed as described above to 
remove the RNA substrate and products and then transferred to another reaction 
solution. Crystals were stored at 4 °C in MFJ buffer for cycles performed on different 
days. 
8.5 Western blot and dot blot analyses 
12.5 µL of the 25 µL MFJ buffer containing a dissolved protein-coated RNase 
A-infused DNA crystal was used for either western blot or dot blot analysis. For 
western blotting, proteins were separated in 15% SDS-PAGE and transferred to 
PVDF membrane using Bio-Rad Mini-PROTEAN tank transfer unit. For dot blotting, 
protein solution was directly added onto nitrocellulose membrane (0.2 µm pore size) 
and air-dried. Immunodetection was performed using primary antibody against 
bovine RNase A (ab6610, Abcam, UK) and secondary antibody against rabbit IgG 
(ab6802, Abcam, UK). The results were visualized by using ECL kit (SuperSignal 
West Pico Chemiluminescent Substrate, Thermo Fisher Scientific, USA). 




8.6 Confocal microscopy imaging 
Confocal fluorescence microscopy was performed on a Leica SP5 X Confocal 
Microscope at room temperature (λexcit = 488 nm). To initiate the catalytic reaction by 
RNase A, 1.5 µL of RNA substrate was added into 100 µL of MFJ solution (Final 
concentration for RNA substrate is 2 µM) containing a protein coated RNase A-




Chapter 9:  Enzyme-infused DNA Crystals as Biocatalyst 
 
9.1 Using RNase A as a model enzyme with dinucleotide RNA substrate/MBP-RNase 
inhibitor 
Bovine pancreatic RNase A was chosen as a model enzyme for this study. 
RNase A is ~14 kDa,71 placing it within the range of proteins that can be absorbed 
into the crystal's channels61. It is also highly stable in a variety of reaction conditions 
and can be assayed using a wide variety of substrates.72 This study utilized a 
quenched fluorescent rUA dinucleotide, similar to those used in previous studies73. 
The dinucleotide contained 5' dabcyl and 3' fluorescein moieties to enable 
fluorescence release upon cleavage of the scissile phosphodiester linkage (Figure 
9.1). Importantly, RNase A is also potently inhibited by the protein RNase inhibitor 
through tight interactions with a femtomolar dissociation constant.70 With a molecular 
weight of ~50 kDa, RNase inhibitor is significantly larger than RNase A, placing it 
slightly above the size limit of proteins that were detected in the crystal interior. 
However, to avoid RNase inhibitor potentially inhibiting RNase A inside the crystals, 
an MBP-RNase inhibitor fusion protein (90 kDa; see Chapter 8) was constructed and 
used interchangeably with commercially available RNase inhibitor. 
DNA crystals were loaded with RNase A by soaking 4 days in 44 mg/mL 
RNase A at 4 °C. Crystals were washed extensively with buffer before being 
incubated with RNase inhibitor or MBP-RNase inhibitor prior to initiating reactions. 
Pilot experiments using washed and dissolved crystals established the amount of 
inhibitor necessary to inhibit all of the RNase present in a medium-sized crystal 




4-times this amount of inhibitor to ensure its excess. Immunoblot analysis from 









Figure 9.1 - Schematic representation of the fluorescence assays 
A single DNA crystal is infused with RNase A and then transferred to buffer 
containing excessive RNase inhibitor or MBP-RNase inhibitor. The RNase A on the 
crystal surface or that has diffused out of the crystal will be bound. A dinucleotide 
RNA substrate containing 5' dabcyl and 3' fluorescein moieties enables fluorescence 
release upon the cleavage of its scissile phosphodiester linkage by RNase A. Direct 
fluorescence assay (Assay 1) is performed within a low-volume fluorescence cuvette 
containing reaction buffer and substrate. Fluorescence accumulation was monitored 
over time without agitation. Indirect assay (Assay 2) is performed by having aliquots 
of the reaction buffer being removed from around the crystals at various time points 
and the fluorescence measured. Multiple cycles of fluorescence assays are performed 
following the removal of substrate and products by washing. For both assays 
excessive RNase inhibitor or MBP-RNase inhibitor is added to the reaction media to 
















Figure 9.2 - Immunoblot analysis from three RNase A-infused crystals.  
Top panel: each crystal was dissolved in 25 µL buffer solution and half of the volume 
was loaded onto a nitrocellulose membrane together with known aqueous RNase A 
samples, followed by immunodetection and imaging. The crystal samples are in red 
circles and the known RNase A samples are in blue circles. Bottom panel: a standard 
curve of dot volume against the input mass of aqueous RNase A samples was made 
from the dot blot. The masses of infused RNase A were obtained by fitting the dot 
volume of the crystal sample into the standard curves and were calculated to be 13.7 
ng, 25.2 ng, and 14.6 ng, respectively. These were the three crystals used for kinetic 







9.2 Direct and indirect fluorometry assays 
RNase A activity of loaded crystals was monitored in two ways as described 
in Figure 9.1. Prepared crystals were transferred directly to a low-volume 
fluorescence cuvette containing reaction buffer and substrate. Fluorescence 
accumulation was monitored over time without agitation (Figure 9.3). For some 
crystals anomalous peaks were observed (Figure 9.4), which were attributed 
primarily to the crystal being in the cuvette light path, but may also be the result of 
mass transfer effects. Following the initial 3 h reaction, crystals were reused by 
washing for at least 30 min to remove substrates and products, incubating with fresh 
inhibitor, and transferring to a new reaction buffer. Similar profiles were observed for 
multiple cycles, but with decreased overall fluorescence, presumably due to the loss 
or inactivation of RNase A during the wash steps. Similar results were obtained when 
the crystals were incubated in the same conditions, but aliquots of the reaction buffer 
were removed from around the crystals at various time points and the fluorescence 
measured (Figure 9.3, inset). There was little change in fluorescence intensity of the 
individual time points over 20 min (Figure 9.5), indicating that any RNase A released 














Figure 9.3 - RNase A activity of DNA crystals.  
Fluorescence intensities of uncoated single crystal versus time (Direct assay) are 
shown in the main panel and bulk solution fluorescence (Indirect assay) at a single 



















Figure 9.4 - An RNase A-infused crystal shows an anomalous peak with sharp 
fluorescence changes.  
The anomalous peaks at ~1h are primarily attributed to the crystal being in the cuvette 



















Figure 9.5 - Released RNase A does not contribute to bulk fluorescence.  
To check if any RNase A released into the solution during the assay or washing steps 
is effectively bound by MBP-RNase inhibitor, an aliquot of the reaction buffer taken 
at 60 minute from the first cycle of a fluorescence assay was monitored for 20 min. 
The absence of any appreciable gain in signal suggests that any RNase A released is 
bound by inhibitor. (The reaction sample with RNase inhibitor has the same kinetic 








Chapter 10: Protective Protein-based “Coating” Improves 
Reusability of an Enzyme-infused DNA Crystal 
 
10.1 Reuse experiment 
To improve the reusability of the RNase A infused crystals, a coating 
technique was developed to prevent the loss of enzyme. Washed crystals were 
incubated with 30 mg/mL hen egg-white lysozyme solutions for 5 min, and then 
transferred to fresh buffer containing 2% glutaraldehyde for 20 min. Western blot 
analysis did not show higher molecular weight RNase A (Figure 10.1), indicating 
that under these conditions there was little intermolecular crosslinking of the enzyme. 
Utilizing both assay methods described above, RNase activity profiles for coated 
crystals were maintained over sequential cycles (Figure 10.2), with up to 4 days 
between cycles (Figure 10.3). 
 
 
Figure 10.1 - Western blot result of a dissolved RNase-infused crystal.  
No significant higher molecular weight RNase A is observed, indicating little or no 




















Figure 10.2 - RNase A activity of protein-coated DNA crystals.  
Fluorescence intensities of lysozyme-coated single crystal versus time (direct assay) 
are shown in the main panel and bulk solution fluorescence (Indirect assay) at a single 
time point (60') for different crystals are shown in the inset. Only 2 cycles are shown 





















Figure 10.3 - Reusability test of a protein-coated RNase A-infused crystal.  
Crystal activity profiles are maintained at the same level over multiple sequential 







10.2 Steady-state kinetic parameters for encapsulated enzyme 
Having crystals that retained activity over multiple cycles allowed me to 
attempt to determine steady-state kinetic parameters for the encapsulated enzymes. 
Single lysozyme-coated crystals were incubated at 7 different substrate 
concentrations sequentially. Aliquots of the reactions were taken at various time 
points and used to determine initial reaction velocities. Multiple crystals showed good 
agreement and little difference when the reaction series were done with ascending or 
descending substrate concentrations. Initial velocities plotted vs. substrate 
concentrations showed non-hyperbolic saturation kinetics in the measurable substrate 
range (Figure 10.4). This non-Michaelis-Menten behavior is consistent with other 
examples of immobilized enzymes62-67 and can be attributed to the significant mass 
transfer effects resulting from both external and internal diffusion of substrates and 
products in such large crystals. These effects can be mitigated at high substrate 
concentrations,64 but in this case, testing higher substrate concentrations proved 
intractable due to the difficulty in obtaining early time points in the linear range. 
Importantly, because the free enzyme does follow Michaelis-Menten kinetics,74 this 
result further supports the conclusion that the observed dinucleotide cleavage events 













Figure 10.4 - Non-Michaelis-Menten kinetics of RNase A infused crystals.  
Initial velocities determined from 7 substrate concentrations for three independent 
crystals were plotted versus substrate concentrations. These show non-hyperbolic 
substrate dependence. Similar results were obtained with ascending or descending 







10.3 Confocal fluorescence microscopy 
Confocal microscopy was used to directly visualize the release of fluorescence 
signal from the crystal (Figure 10.5). Substrate was added to standard reaction 
conditions containing the crystal and multiple planes were imaged over time. 
Depending on substrate concentration, detectable localized fluorescence release that 
was initially most intense around the periphery of the crystal, was observed within 12 
min. However, within minutes the interior fluorescence had achieved comparable 
levels. This is consistent with the encapsulated enzymes closest to the crystal 
periphery being likely to contact substrate first, while diffusion effects limit substrate 
accessibility to the more deeply buried enzymes. Interestingly, even at late time 
points, there was greater fluorescence apparent at six-fold ends of the crystal 
periphery, possibly indicating preferential product release from the much larger 












Figure 10.5 - Confocal microscopy of RNA substrate cleavage by a DNA crystal.  
RNA substrate with a final concentration of 2 µM was added to a single RNase A-





Chapter 11:  Summary and concluding remarks 
 
11.1 Summary of results 
Three-dimensional DNA crystals have long been envisioned as containers for 
biocatalysis. By using RNase A as a model enzyme system I have demonstrated that 
the crystals infused with enzyme can cleave a dinucleotide substrate with kinetic 
parameters similar to other reported immobilized enzyme systems62-67. The axially 
distinct aperture sizes in the crystal design allowed me to improve encapsulation of 
the enzyme with a protective protein-based “coating” cross-linked around the crystal 
surface. This coating allows entry and exit of small molecules through the crystal 
while restricting enzymes inside the crystal. The enzyme-infused DNA crystal is 
capable of performing multiple cycles of catalysis and retaining its enzymatic activity 
over numerous days after being protein-coated.  
11.2 Contributions to present knowledge and future implications 
The concepts of the enzyme-infused DNA crystal and the unique protein 
coating technique provide possibilities to the development of modular solid-state 
catalysts. The development of solid-state enzymatic catalysts in a DNA framework 
may have a number of advantages over other crystal-based biocatalysis systems.64-67 
Most significant of these may be the potential to develop modular catalysts by 
incorporating different enzymes into the crystal solvent channels. A natural extension 
of these types of modular crystals would be the introduction for multiple enzymes to 
perform sequential reactions. The observed kinetic restrictions are a problem common 




problem with cross-linked protein crystals is to reduce the particle size. This may be 
achieved with DNA crystals through controlled growth conditions. Though it may be 
necessary in these cases to crystallize the DNA in the presence of the enzymes to 
improve incorporation yields. Similar to cross-linked protein crystals,64-66 these DNA 
crystals are composed entirely of biomolecules. Although the application of enzyme-
infused DNA crystal itself is not a biomedical application, it is biodegradable and 
potentially biocompatible for environmental or biomedical applications. For example, 
it can potentially be used in enzyme replacement therapy by protectively delivering 
specific enzyme to the target organs. 
The DNA crystals used in this study have a relatively constant temperature 
range (> 37°C) over which they become unstable and start to disassemble at a 
relatively fast rate. And we found by using chemical cross-linkers to stabilize the 
inter-strand interaction, the disassemble temperature range could be raised and the 
treated DNA crystals could stay stable for a longer period of time at higher 
temperatures. This discovery will potentially allow researchers to develop a 
temperature-controlled release device using such crystals. Similar to the enzyme 
replacement therapy application using the DNA crystal, a temperature-controlled 
release crystal can deliver specific drugs to inflammatory tissues where temperature is 
slightly higher. However, this application needs a more accurate temperature control 
in both crystal disassemble and drug release, which, at this point, has not been 
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